Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
PLAVIX (clopidogrel) is an oral antiplatelet agent that reduces thrombotic events in patients with acute coronary syndrome, recent myocardial infarction, or peripheral arterial disease. It works by irreversibly inhibiting platelet aggregation, preventing blood clots. This small molecule has been a cornerstone therapy in cardiology for over 25 years.
LOE-stage product with minimal Part D spending signals a mature, commoditized franchise likely in transition mode with potential team restructuring.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
Worked on PLAVIX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPLAVIX offers limited career growth opportunities given its LOE-approaching status and minimal linked job openings. Professionals taking roles on this product should expect focus on defending market share against generics and newer competitors rather than growth and innovation.